Metaclipse Therapeutics Corporation

Metaclipse Therapeutics Corporation is a preclinical biotechnology company based in Atlanta, Georgia. Founded with a small team of 6 employees, the company focuses its efforts on developing innovative cancer therapies. While currently generating $1 million in revenue, Metaclipse Therapeutics aims to expand its reach and impact significantly in the coming years. The company specializes in creating personalized cancer therapies that are meticulously tailored to each patient's unique tumor profile. This approach sets them apart from traditional cancer treatments, which often rely on a one-size-fits-all approach. Metaclipse Therapeutics' initial focus is developing a personalized therapy for triple negative metastatic breast cancer, a particularly challenging form of the disease. Metaclipse Therapeutics' strategy centers on establishing the safety and effectiveness of its therapies through early clinical trials, with the goal of completing these trials by the end of 2019. Following successful trials, the company intends to license its groundbreaking products to major pharmaceutical companies, enabling widespread access to these potentially life-changing treatments. For more information about Metaclipse Therapeutics Corporation and its innovative cancer therapies, visit their website at metaclipse.com.